As of Dec 13
| +0.10 / +5.41%|
The 2 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 8.50, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +335.90% increase from the last price of 1.95.
The current consensus among 2 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.